IgE Inhibits Toll-like Receptor 7- and Toll-like Receptor 9-Mediated Expression of Interferon-α by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus
- PMID: 26991804
- DOI: 10.1002/art.39679
IgE Inhibits Toll-like Receptor 7- and Toll-like Receptor 9-Mediated Expression of Interferon-α by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus
Abstract
Objective: Plasmacytoid dendritic cells (PDCs) play a central role in pathogenesis of systemic lupus erythematosus (SLE) through their unique ability to produce large amounts of type I interferon (IFN) upon Toll-like receptor 7 (TLR-7) and TLR-9 triggering. PDCs express specific surface regulatory receptors involved in negative regulation of IFNα secretion. These receptors use the γ-chain of high-affinity Fc receptor (FcR) for IgE, FcɛRI. We undertook this study to test our hypothesis that IgE engagement of FcɛRI on PDCs may impact IFNα production in SLE patients.
Methods: Serum levels of total IgE were measured in healthy volunteers, SLE patients, and patients with IgE-dependent allergic disorders. FcɛRI expression on PDCs from SLE patients was evaluated by flow cytometry. Purified PDCs were incubated with monoclonal IgE for 24 hours, then stimulated for 18 hours with TLR agonists or immune complexes (ICs). IFNα production by PDCs was detected by quantitative real-time polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay. Expression of TLR-7, TLR-9, and IFN regulatory factor 7 (IRF-7) in PDCs was quantified by quantitative real-time PCR.
Results: We observed significantly higher IgE levels in SLE patients with quiescent disease than in those with active disease. In SLE patients, IgE levels correlated inversely with disease activity. IgE levels were not associated with the presence of antinuclear IgE. Purified PDCs treated for 24 hours with monoclonal IgE up-regulated FcɛRI expression in an IgE dose-dependent manner. IgE-treated PDCs significantly decreased IFNα secretion and down-regulated CCR7 expression upon stimulation with TLR-7 and TLR-9 ligands and ICs from lupus patients. IgE treatment down-regulated expression of TLR-9 and IRF-7.
Conclusion: Our results support the notion that IgE plays a protective role in SLE pathogenesis through the modulation of inflammatory response by PDCs.
© 2016, American College of Rheumatology.
Similar articles
-
C-reactive protein inhibits plasmacytoid dendritic cell interferon responses to autoantibody immune complexes.Arthritis Rheum. 2013 Jul;65(7):1891-901. doi: 10.1002/art.37968. Arthritis Rheum. 2013. PMID: 23576062 Free PMC article.
-
Contrasting mechanisms of interferon-α inhibition by intravenous immunoglobulin after induction by immune complexes versus Toll-like receptor agonists.Arthritis Rheum. 2013 Oct;65(10):2713-23. doi: 10.1002/art.38082. Arthritis Rheum. 2013. PMID: 23840006
-
Up-Regulation of TLR7-Mediated IFN-α Production by Plasmacytoid Dendritic Cells in Patients With Systemic Lupus Erythematosus.Front Immunol. 2018 Aug 28;9:1957. doi: 10.3389/fimmu.2018.01957. eCollection 2018. Front Immunol. 2018. PMID: 30210502 Free PMC article. Clinical Trial.
-
Anti-interferon alpha treatment in SLE.Clin Immunol. 2013 Sep;148(3):303-12. doi: 10.1016/j.clim.2013.02.013. Epub 2013 Mar 1. Clin Immunol. 2013. PMID: 23566912 Review.
-
Potential role of IFNα in adult lupus.Arthritis Res Ther. 2010;12 Suppl 1(Suppl 1):S3. doi: 10.1186/ar2884. Epub 2010 Apr 14. Arthritis Res Ther. 2010. PMID: 20392290 Free PMC article. Review.
Cited by
-
High serum immunoglobulin D levels in systemic lupus erythematosus: more to be found?Clin Rheumatol. 2023 Apr;42(4):1069-1076. doi: 10.1007/s10067-022-06457-9. Epub 2022 Dec 30. Clin Rheumatol. 2023. PMID: 36585530
-
IgE in the Pathogenesis of SLE: From Pathogenic Role to Therapeutic Target.Antibodies (Basel). 2020 Dec 8;9(4):69. doi: 10.3390/antib9040069. Antibodies (Basel). 2020. PMID: 33302566 Free PMC article. Review.
-
Platelets and IgE: Shaping the Innate Immune Response in Systemic Lupus Erythematosus.Clin Rev Allergy Immunol. 2020 Apr;58(2):194-212. doi: 10.1007/s12016-019-08744-x. Clin Rev Allergy Immunol. 2020. PMID: 31254159 Review.
-
Self-reactive IgE and anti-IgE therapy in autoimmune diseases.Front Pharmacol. 2023 Jan 23;14:1112917. doi: 10.3389/fphar.2023.1112917. eCollection 2023. Front Pharmacol. 2023. PMID: 36755957 Free PMC article. Review.
-
Toll-like receptor-9 is involved in the development of B cell stimulating factor-induced systemic lupus erythematosus.Exp Ther Med. 2018 Jan;15(1):585-591. doi: 10.3892/etm.2017.5411. Epub 2017 Oct 31. Exp Ther Med. 2018. PMID: 29387207 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical